ClinicalTrials.gg
RecruitingNCT06969807MSC-DKD-001Updated Jul 14, 2026

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

A Phase 2 interventional study of Amimestrocel in Diabetic Kidney Disease (DKD), sponsored by Chinese PLA General Hospital. Recruiting at 6 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Chinese PLA General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Planned enrollment
27th of 52
120 · median 122
Started
2025
with 6 others
Phase 2
7 of 75
1 open now
Primary completion
2026-08
later than 14 of 29 live
Registered
65th of 75
by date
Lead sponsor
4 of 75
Chinese PLA General Hospital

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 27th largest by planned enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 14 of the 29 other live ones, and was the 65th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can improve renal function or proteinuria of DKD patients.

03

Conditions studied

  • Diabetic Kidney Disease (DKD)

Keywords

  • mesenchymal stromal cells(MSCs)
  • Diabetic kidney disease (DKD)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: -

  1. Men and women who are ≥18 and ≤ 80 years old.
  2. Diagnosed with type 2 diabetes mellitus.
  3. Diagnosed with diabetic kidney disease based on renal pathology within the past 10 years.
  4. The 24-hour urine protein quantification is continuously ≥ 3.5 g, or the urine albumin-to-creatinine ratio (UACR) > 1000 mg/g.
  5. The estimated (eGFR) ≥ 15 ml/min/1.73m² (calculated according to the CKD-EPI formula).
  6. The blood pressure can be controlled at BP ≤ 160/100 mmHg.
  7. (HbA1c) \< 9%.
  8. Willing and able to provide written .

Exclusion Criteria:

  1. Patients with kidney diseases not caused by diabetes mellitus.
  2. Patients who have received treatment with systemic (such as cyclosporine A, tacrolimus, mycophenolate mofetil, etc.) within 30 days before enrollment and the duration of treatment exceeds one week.
  3. Severe cardiovascular diseases, such as congenital heart diseases, atrial fibrillation, class Ⅲ-IV, unstable angina pectoris, etc.
  4. A history of cerebral hemorrhage or cerebral infarction within the past six months (except for those with a history of lacunar cerebral infarction without residual limb movement disorders, cognitive and language function disorders).
  5. Patients with severe hyperlipidemia: (serum triglyceride ≥ 6.2 mmol/L, serum low-density lipoprotein cholesterol ≥ 4.1 mmol/L).
  6. Hyperkalemia that cannot be controlled through diet or potassium-lowering treatment.
  7. Patients with active infections of or viruses (the copy number of HBV DNA or HCV RNA exceeds the value); patients with active tuberculosis; patients with severe immunodeficiency diseases, (HIV) infection, etc.
  8. Patients with a history of malignant tumors within the past five years.
  9. Patients with a known history of severe allergy to component blood or blood products, or patients with a history of allergy to heterologous proteins.
  10. Lactating women, or female patients who have a pregnancy plan or an egg donation plan from the start of the study to the follow-up period, and male patients (or their partners) who have a childbearing plan or a sperm donation plan from the start of the study to the follow-up period and are unwilling to take measures.
  11. Active infection within one week before enrollment and requiring treatment with intravenous antibiotics.
  12. Patients who have participated in other interventional clinical trials within three months before enrollment.
  13. The research physician deems that the patient's condition is not suitable for participating in this clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Amimestrocel

    patients receive standard treatment and Amimestrocel is administered via Intravenous infusion on day 1, 14, 28, and week 8, 12, 16, 20, 24.

    Drug: Amimestrocel

Interventions

  • DrugAmimestrocel

    In the first month (day 1, 14, 28): 1×10\^6 cells per kilogram. From the 8th to the 24th week (week 8, 12, 16, 20, 24): 1.5×10\^6 cells per kilogram.

06

What researchers measure

Primary outcomes

  1. Urine protein

    Urine protein will be measured on 24h urine samples

    Time frame: Change from baseline at 24 weeks

  2. estimated Glomerular Filtration Rate(eGFR)

    GFR will be estimated by CKD-EPI

    Time frame: Change from baseline at 24 weeks

Secondary outcomes

  1. fasting blood glucose

    fasting blood glucose

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  2. HbA1c

    Glycated Hemoglobin A1c

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  3. Urinary Albumin/Creatinine Ratio(UACR)

    UACR will be measured on spot morning urine samples

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  4. proportion of outcome ( ≥50% declined in eGFR,reached end stage renal disease (ESRD), or occured Renal replacement)

    proportion of outcome ( ≥50% declined in eGFR,reached End Stage Renal Disease (ESRD), or occured Renal Replacement Therapy)

    Time frame: proportion of study participants within outcome at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  5. proportion of major adverse cardiac events(MACE) and all-cause mortality

    proportion of major adverse cardiac events(MACE:CV death, non-fatal CV event(myocardial infarction, stroke, hospitalization for HF)) and all-cause mortality

    Time frame: proportion of study participants within outcome at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  6. Mechanism exploration

    Explore the mechanism through blood tests(Serum/plasma concentrations (pg/ml) of biomarkers of inflammation. Proportion/total number of circulating T cells, B cells, NK cells, etc ).

    Time frame: Change from baseline at 4,12,24 weeks and 12 months

  7. changes in retinal imaging

    Macular vascular density by Optical Coherence Tomography Angiography (OCTA), and analyze the percentage of changes in retinal imaging of patients compared to the baseline .

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  8. Changes in peripheral nerve injury

    Examine through electromyography, to evaluate the percentage of changes in peripheral nerve injury of patients compared with the baseline.

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  9. Changes in symptoms

    The traditional Chinese Medicine(TCM)Syndrome Rating Scale will be used to score TCM symptoms,to evaluate the percentage of changes in the symptoms of patients compared with the baseline.

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  10. Changes in the quality of life scale

    The Diabetes Quality-of-Life Measure (DQOL) will be used to score quality of life at each visit, to evaluate the percentage of the change in the DQOL of patients compared to the baseline

    Time frame: Change from baseline at 24 weeks and then every 6 months to study completion, up to 24 months after cell infusion

  11. Adverse Event and Serious Adverse Event(SAE)

    Time frame: within 28 weeks after received Amimestrocel

  12. secondary malignant disease

    Number of Participants with secondary malignant disease

    Time frame: within 24 months after received Amimestrocel

07

Study locations

5 of 6 sites recruiting
  • Beijing Hospital
    Beijing, Beijing Municipality 100010, China
    Recruiting
    • Ban Zhao · Contactzbyule@139.com · 86 13910425475
    • yonghui Mao · Principal investigator
    • ban Zhao · Sub investigator
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
    Recruiting
    • shunlai Shang · Contact18810568600@163.com · 86 17732215650
    • wenge Li · Principal investigator
    • shunlai Shang · Sub investigator
  • Capital Medical University Affiliated Beijing Friendship Hospital
    Beijing, Beijing Municipality 100050, China
    Recruiting
    • dai Deng · Contactdazziling@163.com · 86 01063138772
    • hongdong Huang · Principal investigator
    • dai Deng · Sub investigator
  • Xuanwu Hospital, Capital Medical University
    Beijing, Beijing Municipality 100053, China
    Recruiting
    • xingtong Dong · Contactzhangaihua0982@sina.com · 86 156 9995 9558
    • aihua Zhang · Principal investigator
    • xingtong Dong · Sub investigator
  • Chinese PLA General Hospital
    Beijing, Beijing Municipality 100853, China
    Recruiting
  • Beijing Tsinghua Changgung Hospital, Medical Center, Tsinghua University
    Beijing, Beijing Municipality 102218, China
    Not yet recruiting
    • minxia Li · Contactlyha01051@btch.edu.cn · 86 13810136821
    • yuehong Li · Principal investigator
    • minxia Li · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2026, 14 months after the start.

Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 14, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Aug 15, 2026
CompletionEst.
May 15, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06969807
Responsible party
Chen Xiangmei (Principal Investigator, Chinese PLA General Hospital) — Principal investigator
First posted
May 14, 2025
Start date
Jun 9, 2025
Primary completion
Aug 15, 2026 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

xiangmei chen
Contact
liping.8@163.com
+86 010 66935462

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion